Evidence map›Paper›PMID 41427225›Full record

ArticleACS omega2025

Structure-Based Discovery of Potent and Selective Small-Molecule α5β1 Integrin Inhibitors for Asthma Therapy.

Richard Beresis, Aparna Sundaram, Hyunil Jo, Marc Adler, Zheng Wang, Joel McIntosh, Seul Ki Yeon, Qiuya Huang, Grace Ngo, Dean Sheppard and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Richard BeresisDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.
Aparna SundaramDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, California 94143, United States.
Hyunil JoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-4863-0779
Marc AdlerChemPartner-San Francisco, 280 Utah Avenue, South San Francisco, California 94080, United States.
Zheng WangChemPartner-Chengdu, Tianfu Life Science Park, No. 88, Keyuan South Road, Hi-Tech Zone, Chengdu, Sichuan 610041, China.
Joel McIntoshNurix Inc, San Francisco, California 94158, United States.
Seul Ki YeonDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.
Qiuya HuangChemPartner-Chengdu, Tianfu Life Science Park, No. 88, Keyuan South Road, Hi-Tech Zone, Chengdu, Sichuan 610041, China.
Grace NgoDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, California 94143, United States.
Dean SheppardDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, California 94143, United States.
William F DeGradoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-4745-263X

Funding

Mechanisms of Cytokine-Mediated Integrin Activation and Force Transmission in Airway Smooth MuscleR01HL173342 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aparna Bala Sundaram · 2024 to 2026
$1.9M
NHLBI NIH HHS R01 HL173342
6 · The paper itself

Abstract

Integrin α5β1 is the principal fibronectin-binding integrin in airway smooth muscle (ASM), and its modulation attenuates airway narrowing induced by asthmagenic cytokines in mouse models of allergic asthma. These findings highlight small molecule α5β1 inhibition as a promising therapeutic strategy. Although inhalation is the preferred route for asthma therapy, previously reported α5β1 antagonists lacked sufficient potency, selectivity, or inhalation pharmacokinetic data. Here, we report a potent series of α5β1 inhibitors identified through structure-based design and sequential optimization. Lead compound

Identifiers

PMID41427225
PMCPMC12713449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.